Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

Placebo, Leukotriene Antagonist, or CorticoSteroids for Mild Persistent Asthma (PLASMA) Leukotrienes antagonists have been shown to reduce the incidence of steroid-requiring exacerbations, and some studies have suggested that they can be used to reduce or substitute for ICS [10-13]. Oral leukotriene antagonists are now commonly prescribed for patients with asthma, possibly because patients have been shown to be more likely to comply with regular oral therapy than with regular inhaled therapy [14]. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. www.acrn.org /plasma.html   (1777 words)

Asthma Grand Rounds: Drazen; Leukotriene Modifying Drugs: Two Years' Experience Leukotrienes received their name because they were originally found in leukocytes and because they contain three double carbon bonds in a row, making their chemical structure a conjugated triene. The leukotriene receptor antagonists, montelukast (Singulair®) and zafirlukast (Accolate®), are of approximately equivalent potency. It is clear from studies that have compared the response to leukotriene receptor antagonists with inhaled corticosteroids that the latter result in a greater overall improvement in lung function. www.asthma.partners.org /NewFiles/DrazenLeukotriene2.html   (2648 words)

CYSLTR1 - cysteinyl leukotriene receptor 1   (Site not responding. Last check: 2007-10-10) Leukotriene (LT) D4 is involved in antigen-induced asthma: a study with the LTD4 receptor antagonist, MK-571. The LT antagonists developed in asthma are mainly specific for a receptor subtype, the CysLT1 receptor, involved in the bronchoconstrictor and inflammatory effects of sulfidopeptide leukotrienes (LTC4, D4 and E4). CYSLTR1 is a homologue of Cysltr1 (cysteinyl leukotriene receptor 1) from Mus musculus. www.ihop-net.org /UniPub/iHOP/gi/95849.html   (2735 words)

Leukotriene Receptor Antagonist In medicine and biology, an antagonist is a substance that inhibits the normal physiological function of a receptor. Antagonists that compete with an agonist for a receptor are competitive antagonists. Angiotensin II receptor antagonists are primarily used for the treatment of hypertension where the patient is intolerant of ACE inhibitor therapy. www.frozenup.com /pages9/50/leukotriene-receptor-antagonist.html   (339 words)

All Abstracts for Sydney 2000   (Site not responding. Last check: 2007-10-10) Leukotriene antagonist (zafirlukast) therapy in pediatric dermatological diseases The place of the leukotriene antagonists in the therapeutical regimens of these diseases are discussed. Leukotriene antagonist treatment is advised to include into the therapeutical regimen in severe pediatric allergic dermatological diseases. www.hogrefe.de /Sydney2000/abstracts/O-191.html   (211 words)

Are leukotriene receptor antagonists effective therapy for Allergic Rhinitis Leukotrienes serve as inflammatory cell mediators with actions that include bronchoconstriction by smooth muscle contraction, bronchial hyper-responsiveness, inflammatory cell accumulation and chemotaxis, mucus hypersecretion, neuronal stimulation, and increased microvascular permeability. Leukotriene C4, D4, and E4 are referred to as the cysteinyl leukotrienes. Leukotriene modifiers are a valuable treatment for the 10% of chronic asthmatics who have aspirin-sensitive asthma for which over-expression of leukotriene C4 synthetase has been implicated. intmedweb.wfubmc.edu /grand_rounds/2000/leukotriene.html   (4927 words)

Allergy & Asthma Disease Management Center: Ask the Expert: Leukotriene The leukotriene receptor antagonists, montelukast, zafirlukast, and pranlukast, and the 5-lipoxygenase inhibitor, zileuton, are unique in their ability to target specific components of asthmatic inflammation. The leukotrienes are a family of lipid mediators that appear to play an important role in the symptomology and pathogenesis of asthma. Leukotriene antagonists (e.g.) such as Accolate are also used in the treatment of mild asthma, particularly if there is "triad asthma" with nasal polyps and aspirin-induced asthma (where leukotriene release is reportedly much increased). www.aaaai.org /aadmc/ate/leukotriene.html   (5187 words)

CHEST: Pharmacology of leukotriene receptor antagonists: more than inhibitors of bronchoconstriction - Asthma ...   (Site not responding. Last check: 2007-10-10) Leukotriene [D.sub.4] is an important mediator of antigen-induced bronchoconstriction: attenuation of dual response with MK-571, a specific [LTD.sub.4] receptor antagonist [abstract 213]. Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent leukotriene [D.sub.4] receptor antagonist. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. www.findarticles.com /p/articles/mi_m0984/is_n2_v111/ai_19175070/pg_6   (950 words)

Accolate - Highly potent and selective cysteinyl leukotriene receptor antagonist Cysteinyl leukotrienes C4, D4, and E4 are important inflammatory mediators of asthma. Accolate is a potent, competitive antagonist of CysLT1 receptor. Stimuli of asthma cause cells in the airway to produce leukotrienes which cause many of the signs and symptoms of asthma. www.az-air.com /phy_prod/accolate_highly_potent.asp   (148 words)

Randomized Placebo-controlled Study Comparing a Leukotriene Receptor Antagonist and a Nasal Glucocorticoid in Seasonal ... antagonist in early allergic reactions in the nose (10). Leukotriene antagonists are to date available only for the treatment of asthma. The effect of a leukotriene antagonist on the early response to antigen. ajrccm.atsjournals.org /cgi/content/full/159/6/1814   (3300 words)

Leukotriene antagonist intermediates - Patent 5105017 This invention provides novel benzene derivatives which are leukotriene antagonists, formulations of those derivatives, intermediates for preparing the derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes. It is the object of this invention to provide novel chemical agents which are selective leukotriene antagonists that can be used therapeutically in the treatment of allergic disorders such as asthma, where leukotrienes are thought to be causal mediators. The amount of leukotriene which is considered to be excessive will depend on a variety of factors, including the specific leukotriene(s) involved, the amount of leukotriene required to cause the particular condition, and the species of the mammal involved. www.freepatentsonline.com /5105017.html   (6989 words)

Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients ... Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma -- Nakamura et al. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma Leukotrienes, LTC4 and B4 in bronchoalveolar lavage in bronchial asthma and respiratory diseases. thorax.bmjjournals.com /cgi/content/full/53/10/835   (3477 words)

From Bench to Bedside . The Hurdles of Discovering a New Leukotriene Receptor Antagonist -- RODGER 161 (2): 7 -- ... antagonist L-649,923 on the response to inhaled antigen in asthma. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J. Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. ajrccm.atsjournals.org /cgi/content/full/161/2/S1/S7   (2356 words)

Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate ... Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials the 5-lipoxygenase inhibitor zileuton and the leukotriene receptor Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. thorax.bmjjournals.com /cgi/content/full/55/6/478   (3614 words)

Leukotriene receptor antagonist therapy -- Dempsey 76 (902): 767 -- Postgraduate Medical Journal Leukotriene receptor antagonists (LTRA) are a new class of drugs for asthma treatment, available in tablet form. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. pmj.bmjjournals.com /cgi/content/full/76/902/767   (3158 words)

Leukotriene Inhibitors   (Site not responding. Last check: 2007-10-10) Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5- lipoxygenase inhibitors. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. www.umdnj.edu /rspthweb/bibs/leukoinh.htm   (1017 words)

Zileuton Leukotriene antagonist used in prophylaxis and chronic treatment of asthma. The purpose of this 12-month, parallel-group, open-label study was to assess the efficacy of zileuton and evaluate liver function in patients treated with this drug (approximately 2% of patients treated with zileuton in controlled trials had reversible liver enzyme elevations). This review will consider the biochemistry of the leukotrienes, their biologic role in asthma, and the therapeutic potential of drugs that alter the production or action of leukotrienes, as well as provide guidelines for the use of leukotriene modifiers in patients with asthma. www.dentalarticles.com /drugs/115.php   (958 words)

Patent 6,939,674 Correlations between polymorphisms in the 5-lipoxygenase gene, or polymorphisms in the leukotriene C4 synthase gene, and a subject's phenotypic response to treatment with a leukotriene receptor antagonist for respiratory disease are described. According to the present methods, a subject who suffers from asthma that is potentially treatable with an anti-inflammatory inhaled glucocorticoid or a leukotriene antagonist, is genetically screened, to aid in predicting their response to such treatment. As used herein, asthma treatable with an anti-inflammatory glucocorticoid or treatable with a leukotriene receptor antagonist is a disease in which the administration of such a drug (in an appropriate pharmaceutical formulation, and in a therapeutically effective amount) has been shown to reduce or alleviate symptoms, without causing unacceptable side effects. www.pharmcast.com /Patents100/Yr2005/Sept2005/090605/6939674_Respiratory090605.htm   (4421 words)

Use of leukotriene receptor antagonist for treatment of scarring - Patent 6951869   (Site not responding. Last check: 2007-10-10) In 1979, the term "leukotrienes" was given to a family of lipid mediators that were derived from their cell source (leukocytes). Pharmaceutical compositions comprising the montelukast compounds are also disclosed as containing inhibitors of the biosynthesis of the leukotrienes such as are disclosed in EP 138,481 (Apr. 24, 1985), EP 115,394 (Aug. 8, 1984), EP 136,893 (Apr. 10, 1985), and EP 140,709 (May 8, 1985), which are hereby incorporated herein by reference in their entirety. The montelukast compounds may also be used in combination with leukotriene antagonists such as those disclosed in EP 106,565 (Apr. 25, 1984) and EP 104,885 (Apr. 4, 1984) which are hereby incorporated herein by reference in their entirety and others known in the art such as those disclosed in EP Application Nos. www.freepatentsonline.com:9003 /6951869.html   (4587 words)

Leukotriene Modifiers - Drug Comparisons - Compare Drugs - DrugDigest Leukotriene modifiers are the newest class of drugs for the treatment of asthma. Leukotrienes are chemical compounds in the body that contribute to airway obstruction and are released during the inflammatory process (which occurs in asthma). Two types of leukotriene - based medications have been developed: leukotriene inhibitors that interfere with the actual synthesis of leukotrienes, and leukotriene antagonists that block the action of leukotrienes by blocking leukotriene receptor sites. www.drugdigest.org /DD/PrintablePages/Comparisons/1,20038,42-5,00.html   (1077 words)

The Preclinical Pharmacological Profile of the Potent and Selective Leukotriene B4 Antagonist CP-195543 -- Showell et ... Findlay SR, Barden JM, Easley CB and Glass M (1992) Effect of the oral leukotriene antagonist ICI 204,219 on antigen-induced bronchoconstriction in subjects with asthma. Henderson WR (1994) The role of leukotrienes in inflammation. Taylor IK, O'Shaughnessy KM, Fuller RW and Dollery CT (1991) Effect of cysteinyl leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. jpet.aspetjournals.org /cgi/content/full/285/3/946   (6051 words)

Oral Leukotriene Antagonist Guidelines Oral leukotriene antagonists are a new class of treatment for asthma.They selectively bind to CysLT1 receptors, preventing the leukotriene inflammatory mediators from exerting their effects. Their future role in the management of asthma is still unclear, however advantages include administration by the oral route, which may aid compliance and be of benefit in patients with poor inhaler technique. Problems with leukotriene antagonists include their cost (although this is comparable with Serevent ®) and side-effects which include headache, thirst, dizziness and fatigue. www.allaboutpharmacy.co.uk /Formulary/Oral_Leukotriene_Antagonist_Guidelines.htm   (349 words)

Antileukotrienes in the Treatment of Asthma -- O'Byrne et al. 127 (6): 472 -- Annals of Internal Medicine The cysteinyl leukotrienes are the primary mediators of the The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. www.annals.org /cgi/content/full/127/6/472   (5548 words)

Leukotriene receptor antagonist reduces need for inhaled corticosteroids -- 319 (7202): 0 -- BMJ Leukotriene receptor antagonist reduces need for inhaled corticosteroids -- 319 (7202): 0 -- BMJ Leukotriene receptor antagonist reduces need for inhaled corticosteroids The leukotriene receptor antagonist montelukast allows asthmatic patients to reduce their use of inhaled corticosteroids, bmj.bmjjournals.com /cgi/content/full/319/7202/0/e   (123 words)

CHEST: Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of ...   (Site not responding. Last check: 2007-10-10) Conclusions: A leukotriene receptor antagonist, but not low-dose theophylline, conferred significant additive anti-inflammatory effects to therapy with a low-dose inhaled corticosteroid but not to that with a medium dose of an inhaled corticosteroid. The aim of this study was to evaluate the effects of adding either low-dose oral theophylline or leukotriene receptor antagonist to the treatment of patients with persistent asthma, who already are receiving either a low-to-medium dose of an inhaled corticosteroid. Patients who were recruited were between the ages of 18 and 65 years, with an established diagnosis of mild-moderate persistent asthma requiring prior inhaled steroid use of [less than or equal to] 1000 [micro]g budesonide/beclomethasone dipropionate (BDP) or [less than or equal to] 500 [micro]g fluticasone propionate daily. www.findarticles.com /p/articles/mi_m0984/is_1_122/ai_90098275   (1032 words)

British Journal of Pharmacology - An alternative pathway for metabolism of leukotriene D4: effects on contractions to ...   (Site not responding. Last check: 2007-10-10) The current class of clinically introduced leukotriene receptor antagonists was developed mainly on the basis of functional studies of smooth muscle preparations in vitro, with the guinea-pig trachea and human bronchus being particularly predictive of the therapeutic effects of anti-leukotrienes in human subjects (Dahlén, 2000). In experiments with CysLT receptor antagonists, a dose ratio (DR) of EC values in the presence and absence of antagonist was calculated for each experiment relative to the paired control. DAHLÉN, S.E. (2000) Pharmacological characterization of leukotriene receptors.. www.nature.com /bjp/journal/v133/n7/full/0704180a.html   (5138 words)

MEU Corporate - clinical trials and studies Phase III comparative/additive study involving a leukotriene antagonist and an inhaled steroid. Protective effect of a leukotriene antagonist against exercise induced asthma in adolescents. Assessment of the effect of a leukotriene antagonist on leukotriene D4 induced bronchoconstriction in asthmatic subjects. www.meu.org.uk /clinical_studies.asp   (735 words)

References The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol 1990;85:1067-75. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen induced airway responses in asthmatic subjects in vivo. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase broncho-constriction and airway hyperresponsiveness in asthmatic subjects. www.medscape.com /content/1999/00/41/80/418059/418059_ref.html   (598 words)

Correlation Between Cysteinyl Leukotriene Release From Leukocytes and Clinical Response to a Leukotriene Inhibitor -- ... Correlation Between Cysteinyl Leukotriene Release From Leukocytes and Clinical Response to a Leukotriene Inhibitor -- Terashima et al. response to a leukotriene receptor antagonist, pranlukast, in the leukotriene receptor is inhibited by pranlukast in the lungs www.chestjournal.org /cgi/content/full/122/5/1566   (2624 words)

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.